TNF and myeloid sarcoma: In 2011 Brambilla et al. tested, in a model of MS, the XPro1595 antagonist, which selectively inhibits soluble TNF without affecting transmembrane TNF, comparing its effects to those of the non-selective TNF inhibitor etanercept.